Skip to main content
Premium Trial:

Request an Annual Quote

MDS Sciex Could Benefit from Parent s Restructuring

NEW YORK, Sept. 2 (GenomeWeb News) - MDS Sciex could benefit from its parent company's plans to restructure and focus resources and management on life sciences markets.

 

MDS said yesterday it will restructure its business in order to refocus resources on markets served by its MDS Pharma Services, MDS Nordion, and MDS Sciex units.

 

MDS further plans to reduce its overhead costs and "better align resources and infrastructure costs," according to the company. As part of its restructuring, the company will reduce its workforce by approximately 500 of its 9,000 employees, resulting in savings of $40 million-$45 million in 2006.

 

"A review of company assets which are not part of MDS's core focus is underway and focused on maximization of shareholder value," said MDS President and CEO Stephen DeFalco in a statement.

 

It was not immediately clear how the restructuring will specifically affect MDS Sciex, which makes mass spectrometers for drug discovery and life sciences. MDS Sciex has joint ventures with both Applied Biosystems and PerkinElmer.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.